Home >> Signaling Pathways >> Immunology/Inflammation

Immunology/Inflammation(免疫及炎症)

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

Products for  Immunology/Inflammation

  1. Cat.No. 产品名称 Information
  2. GC74614 Eftozanermin alfa

    ABBV-621

    Eftozanermin alfa(ABBV-621)是第二代肿瘤坏死因子相关凋亡诱导配体受体(TRAIL-R)激动剂。
  3. GC74612 Epcoritamab

    艾可瑞妥单抗; GEN3013

    Epcoritamab (GEN3013)是一种双特异性IgG1抗体,可将t细胞重定向到CD3×CD20+肿瘤细胞。
  4. GC74607 Efineptakin alfa

    NT-17

    Efineptakin alfa (NT-17)是长效重组人IL-7。
  5. GC74605 Simlukafusp alfa

    FAP-IL2v

    Simlukafusp alfa(FAP-IL2v)是一种免疫细胞因子,包含抗成纤维细胞活化蛋白α(FAPα)的抗体和仅结合IL-2Rβγ的IL-2变体。
  6. GC74599 Cobolimab

    考伯利单抗; TSR-022; GSK4069889

    Cobolimab(TSR-022)是一种抗TIM-3单克隆抗体。
  7. GC74590 Pozelimab

    帕泽利单抗; REGN3918

    Pozelimab(REGN3918)是一种全人IgG4抗C5单克隆抗体。
  8. GC74588 Plamotamab

    帕拉莫妥单抗; XmAb-13676

    Plamotamab(XmAb-13676)是一种结合CD3和CD20的人双特异性抗体(bsAb)。
  9. GC74585 Obexelimab

    奥贝利单抗; XmAb5871

    Obexelimab(XmAb5871)是一种人源化抗CD19抗体。
  10. GC74572 Lilotomab

    利洛托单抗; HH1

    Lilotomab(0-40µg/mL;12 d)降低DOHH2和Ramos细胞的克隆性存活。
  11. GC74571 Ligufalimab

    莱法利单抗; AK 117

    Ligufalimab(AK 117)是一种人源化IgG4抗CD47单克隆抗体。
  12. GC74566 Keliximab

    凯利昔单抗; SB-210396; IDEC CE9.1

    Keliximab (SB-210396)是一种嵌合人/猕猴IgG1抗CD4单克隆抗体,对可溶性CD4的Ki值为1.0 nM。
  13. GC74559 Inbakicept Inbakicept是一种二聚体人IL-15受体α (IL-15 Ra)寿司结构域/人IgG1 Fc融合蛋白,是一种IL-15超级激动剂复合物。
  14. GC74552 Gefurulimab

    ALXN-1720

    Gefurulimab(ALXN-1720)是一种来源于人的针对补体C5和白蛋白的双特异性抗体,可结合C5并阻断其激活。
  15. GC74538 Sotevtamab

    索泰妥单抗; 16B5; AB-16B5

    Sotevtamab (16B5)是一种人源IgG2抗聚簇素单克隆抗体(mAb)。
  16. GC74528 Urabrelimab

    SRF-231; SRF231

    Urabrelimab(SRF231)是一种阻断CD47-SIRP相互作用的全人源性抗CD47单克隆抗体。
  17. GC74523 Xeligekimab

    赛立奇单抗; GR 1501

    Xeligekimab (GR 1501)是一种抗人白细胞介素17A (IL-17A)人源化单克隆抗体。
  18. GC74518 Brazikumab

    布雷库单抗; AMG 139; MEDI2070

    Brazikumab (AMG 139)是一种人IgG2单克隆抗体,选择性结合IL-23的p19亚基,对人IL-23的KD为0.138 nM。
  19. GC74515 Benufutamab

    GEN1029

    Benufutamab(GEN1029)是一种死亡受体5(DR5)特异性激动抗体。
  20. GC74501 Adebrelimab

    阿得贝利单抗; SHR-1316

    Adebrelimab(SHR-1316)是一种人源化IgG4单克隆PD-L1(PD-1/PD-L1)抗体。
  21. GC74499 Talacotuzumab

    塔妥珠单抗; JNJ 56022473; CSL 362

    Talacotuzumab(JNJ 56022473;CSL 362)是一种IgG1型完全人源化的CD123中和单克隆抗体,含有修饰的Fc结构。
  22. GC74491 Tucotuzumab

    西莫白介素单抗; Anti-EPCAM Recombinant Antibody; huKS-IL2

    Tucotuzumab (Anti-EPCAM Recombinant Antibody)是一种针对人上皮细胞粘附分子(EpCAM)的抗原特异性IgG1单克隆抗体。
  23. GC74490 Tositumomab

    托西莫单抗; Anti-Human CD20 Recombinant Antibody

    Tositumomab是一种针对CD20抗原的鼠IgG2aλ单克隆抗体,该抗原存在于正常和恶性B淋巴细胞的表面。
  24. GC74488 Sirukumab

    西鲁库单抗; CNTO-136

    Sirukumab(CNTO-136)是一种人源化单克隆抗IL6(白细胞介素相关)IgG1κ抗体。
  25. GC74486 Lexatumumab

    来沙木单抗; HGS-ETR 2; ETR2-ST01

    Lexatumumab(HGS-ETR 2)是一种人激动性TRAIL受体2(TRAIL-R2、DR5、APO-2)IgG4κ型单克隆抗体。
  26. GC74483 Galiximab

    加利昔单抗; IDEC 114; Anti-Human CD80 Recombinant Antibody

    Galiximab (IDEC 114)是一种靶向CD80抗原并阻断CD80 - cd28结合的免疫球蛋白G1 (IgG1) lambda单克隆抗体。
  27. GC74482 Drozitumab

    曲齐妥单抗; PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody

    Drozitumab(PRO 95780)是一种结合死亡受体DR5的人激动性单克隆抗体。
  28. GC74477 Tigatuzumab

    替加组单抗; CS-1008; Anti-Human TRAIL-R2 Recombinant Antibody

    Tigatuzumab(CS-1008)是一种靶向死亡受体5(DR5)的人源化IgG1单克隆抗体。
  29. GC74476 Seribantumab

    瑟瑞妥单抗; SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody

    Seribantumab (MM 121)是一种靶向HER3的全人源IgG2单克隆抗体。
  30. GC74471 Camidanlumab

    卡利尤单抗; HuMax-TAC

    Camidanlumab (HuMax-TAC)是一种CD25单克隆抗体。
  31. GC74457 Lunsekimig Lunsekimig是一种抗tslp /IL13/ALB单克隆抗体,由5个顺序连接的可变区重链组成。
  32. GC74451 Enfortumab vedotin-ejfv (solution) Enfortumab vedotin-ejfv (solution)是一种用于治疗尿路上皮癌的抗Nectin-4抗体药物偶联物。
  33. GC74446 Rademikibart

    CBP-201

    Rademikibart (CBP-201)是一种靶向IL-4Rα的人单克隆抗体,与人IL-4Rα表位结合时,KD为20.7 pM。
  34. GC74439 Picankibart Picankibart是一种靶向IL23A的小鼠源性IgG1κ抗体。
  35. GC74425 Casdozokitug

    SRF-388

    CasdozokitugSRF-388是一种针对IL27的IgG1κ抗体。
  36. GC74423 Vamikibart Vamikibart是一种靶向IL6的嵌合人源化IgG2κ抗体。
  37. GC74402 HYNIC-iPSMA TFA HYNIC-iPSMA TFA是肿瘤分子成像的配体。nic ipsma由两个成分组成:nic(6-恶嗪诺丁酰胺)和ipsma(前列腺特异性膜抗原抑制剂)。
  38. GC74354 Pegcetacoplan acetate Pegcetacoplan acetate是一种聚乙二醇化的补体C3抑制剂肽。
  39. GC74339 Ac2-26 ammonium Ac2-26 ammonium是膜联蛋白1的n端肽,具有抗炎活性。
  40. GC74335 Icotrokinra

    JNJ-77242113; JNJ-2113; PN-235

    Icotrokinra (JNJ-77242113)是一种口服的选择性IL-23受体拮抗剂。
  41. GC74332 N188 TFA N188 TFA是一种基于双环肽骨架的放射性配体,靶向连接素-4,这是一种在许多肿瘤中过度表达的蛋白质。
  42. GC74317 S7 S7是一种IL-6受体拮抗剂,抑制IL-6和IL-6R之间的结合。
  43. GC74313 MYBMIM MYBMIM是MYB:CBP/P300复合物分子组装的抑制剂。
  44. GC74307 3BP-3940 3BP-3940是一种用于治疗诊断的高效成纤维细胞活化蛋白(FAP)靶向肽。
  45. GC74304 PSMA targeting peptide TFA

    PSMA-1 TFA

    PSMA targeting peptide TFA(PSMA-1 TFA)是一种PSMA靶向肽(GRFLTGGTGRLLRIS),可用于在PCa细胞中靶向递送葡萄糖调节蛋白(GRP)沉默siRNA。
  46. GC74298 Oxidized low density lipoprotein (Human)

    Human ox-LDL

    Oxidized low density lipoprotein (Human)人ox-LDL参与动脉粥样硬化的形成。

  47. GC74270 Penduletin Penduletin是一种黄酮类化合物,可以从白蜡和牡荆中分离出来。
  48. GC74267 Propylparaben-d4

    尼泊金丙酯-d4; Propyl parahydroxybenzoate-d4; Propyl 4-hydroxybenzoate-d4

    Propylparaben-d4是氘标记的尼泊金丙酯。
  49. GC74256 Condurango glycoside A Condurango glycoside A是p53的激活剂。
  50. GC74252 Euphornin Euphornin是一种抗癌剂,可从E. helioscopia中分离得到。
  51. GC74247 (+)-Glaucarubinone (+)-Glaucarubinone是一种强效的AP-1激活蛋白-1抑制剂,EC50值为0.13µM。

Items 51 to 100 of 4267 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction